Clinical trials: Non Organic Psychosis
Type 2 Diabetes Mellitus, Schizophrenia
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population.
- Conditions
- Type 2 Diabetes Mellitus, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- Healthy_LIFE (NCT01828931)
- Testing
- Lifestyle Intervention, Usual Care
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis Nos/Other
Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis
The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed…
- Trial name
- NONSTOP (NCT01765829)
- Testing
- Discontinuation antipsychotic treatment, Antipsychotic treatment
- Where
- 17 sites in Spain
- Volunteers
- 104 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Clinical High Risk for Psychosis (CHR)
Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis
The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment.
- Trial name
- EM-PREPS (NCT06870305)
- Testing
- MBTP : Mindflulness based training for psychosis
- Where
- 2 sites in France
- Volunteers
- 270 people
- Sponsor
- Centre Psychothérapique de Nancy
Schizophrenia Disorders
Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy
The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals with schizophrenia-spectrum disorders. The main questions are: 1.
- Trial name
- VIP (NCT06835556)
- Testing
- Cognitive Behavioral Therapy, TAU
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Vanderbilt University Medical Center
Psychotic Disorders
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
There is a substantial need for enhancing the efficacy and effectiveness of Veterans Health Administration (VHA) inpatient services for psychosis and tailoring them to support recovery.
- Trial name
- ACT-IP (NCT01981356)
- Testing
- Acceptance and Commitment Therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia, Alzheimer's Disease Psychosis
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.
- Trial name
- NCT06556966
- Testing
- LY03020
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
Horyzons: Implementation in Clinical Practice
A clinical trial investigating the feasibility and acceptability of implementing a moderated online social media platform with therapeutic content, Horyzons, as a part of care received at first-episode psychosis (FEP) clinics…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
- Trial name
- NCT04673851
- Testing
- Horyzons USA
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychotic Disorder
Yoga and Aerobic Exercise in Psychosis
The current study aims to evaluate the impacts of yoga and aerobic exercise on neuro-cognitive function, symptoms and brain changes in early psychosis.
- Trial name
- YEP (NCT01207219)
- Testing
- Yoga therapy, Aerobic exercise
- Where
- Hong Kong
- Volunteers
- 140 people
- Sponsor
- The University of Hong Kong
Parkinson Disease, Parkinson Disease Psychosis
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Parkinson's disease psychosis encompasses a range of symptoms, including minor phenomena, frank hallucinations, and delusions. Minor phenomena include passage hallucinations (fleeting sense of a person, animal or object passing…
- Conditions
- Parkinson Disease, Parkinson Disease Psychosis, Hallucinations, Delusion
- Trial name
- NCT05240339
- Testing
- Observation of minor phenomena
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Rochester
Cognitive Dysfunction
GABA-glutamate Interactions and Psychosis
This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy…
- Trial name
- NCT00611572
- Testing
- iomazenil
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Psychosis
Enhancement of Treatment of Delusions in Schizophrenia Through Neuromodulation
The proposed study aims to use a form of neuromodulation, known as transcranial alternating current stimulation (tACS), to improve the effectiveness of the metacognitive training (MCT) program for treatment of delusions in…
- Conditions
- Schizophrenia, Psychosis, Delusions
- Trial name
- tACS (NCT03062553)
- Testing
- Metacognitive Training (MCT), transcranial alternating current stimulation (tACS)
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of British Columbia
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Psychotic Disorders, Schizophrenia
Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
Individuals living with a psychotic disorder often experience changes to their thinking and social skills that can lead to challenges with work, school, relationships and living independently.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT05973110
- Testing
- Cognitive Remediation, Active Control
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Bipolar Disorder
Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder
This study will evaluate the effectiveness of interpersonal and social rhythm therapy (IPSRT) versus clinical status and symptom response therapy (CSSRT) in reinforcing the treatment of bipolar disorder in individuals who are…
- Trial name
- NCT00227968
- Testing
- Interpersonal Social Rhythm Therapy (IPSRT), Clinical Status and Symptom Response Therapy (CSSRT)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of Pittsburgh
Psychotic Disorders, Autism Spectrum Disorder
EEG Microstates Across At-Risk Mental States
The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6).
- Conditions
- Psychotic Disorders, Autism Spectrum Disorder, Major Depressive Disorder, Schizophrenia
- Trial name
- DEMETER (NCT06045897)
- Testing
- EEG 64 channels, Polysomnography 19 electrodes, Light hypnosis
- Where
- France
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Caregiver Burden in Methamphetamine Use Disorder, Expressed Emotions in Caregivers
Effectiveness of Stress Management Training Program For Expressed Emotions in Caregivers of Drug Induced Psychosis Patients Specially Methamphetamine
The main purpose of this study is to evaluate the effectiveness of a Stress Management Training (SMT) program in reducing stress levels among caregivers of individuals suffering from methamphetamine ("ice") addiction and…
- Conditions
- Caregiver Burden in Methamphetamine Use Disorder, Expressed Emotions in Caregivers, Stress Cause Expressed Emotion and Burden
- Trial name
- NCT07714642
- Testing
- O'Connor's (2003) Stress Management Training
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Government College University Faisalabad
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Endocannabinoid Activity Remodulation for Psychosis Liability in Youth
Clinical High-Risk (CHR) for Psychosis is characterized by the occurrence of unusual stressful experiences (attenuated psychotic symptoms, APS), anxious symptoms, psychological distress, and substantial impairment of the…
- Conditions
- Clinical High Risk for Psychosis, Ultra High Risk for Psychosis, Attenuated Psychotic Symptoms
- Trial name
- EARLY (NCT06037993)
- Testing
- Ultra-micronized Palmitoylethanolamide (PEA)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- University of Udine
Autism Spectrum Disorders, Psychosis
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
The purpose of the proposed research is to study the potential changes in biomarkers of patients with neurodevelopmental disorders in response to treatment in clinical trials or in private psychiatry practice utilizing…
- Conditions
- Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
- Trial name
- NCT01364818
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Schizophrenia
Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis: PAFIP
Schizophrenia is a chronic brain disease that is still understood as a condition that limits the development of a normal life for the patient who suffers it and their families.
- Trial name
- 10PAFIP (NCT02200588)
- Where
- Spain
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.